BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ciardiello F, Normanno N, Maiello E, Martinelli E, Troiani T, Pisconti S, Giuliani F, Barone C, Cartenì G, Rachiglio A, Montesarchio V, Tonini G, Rizzi D, Cinieri S, Bordonaro R, Febbraro A, De Vita F, Orditura M, Fenizia F, Lambiase M, Rinaldi A, Tatangelo F, Botti G, Colucci G. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. Annals of Oncology 2014;25:1756-61. [DOI: 10.1093/annonc/mdu230] [Cited by in Crossref: 86] [Cited by in F6Publishing: 76] [Article Influence: 10.8] [Reference Citation Analysis]
Number Citing Articles
1 Martini G, Ciardiello D, Vitiello PP, Napolitano S, Cardone C, Cuomo A, Troiani T, Ciardiello F, Martinelli E. Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? Cancer Treat Rev 2020;86:102023. [PMID: 32474402 DOI: 10.1016/j.ctrv.2020.102023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
2 Di Nicolantonio F, Vitiello PP, Marsoni S, Siena S, Tabernero J, Trusolino L, Bernards R, Bardelli A. Precision oncology in metastatic colorectal cancer - from biology to medicine. Nat Rev Clin Oncol 2021;18:506-25. [PMID: 33864051 DOI: 10.1038/s41571-021-00495-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
3 Papaxoinis G, Kotoula V, Giannoulatou E, Koliou GA, Karavasilis V, Lakis S, Koureas A, Bobos M, Chalaralambous E, Daskalaki E, Chatzopoulos K, Tsironis G, Pazarli E, Chrisafi S, Samantas E, Kaklamanos IG, Varthalitis I, Konstantara A, Syrigos KN, Pentheroudakis G, Pectasides D, Fountzilas G. Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping. Med Oncol 2018;35:101. [PMID: 29855806 DOI: 10.1007/s12032-018-1160-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
4 Chan DLH, Segelov E, Wong RS, Smith A, Herbertson RA, Li BT, Tebbutt N, Price T, Pavlakis N. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. Cochrane Database Syst Rev 2017;6:CD007047. [PMID: 28654140 DOI: 10.1002/14651858.CD007047.pub2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
5 Elez E, Chianese C, Sanz-García E, Martinelli E, Noguerido A, Mancuso FM, Caratù G, Matito J, Grasselli J, Cardone C, Esposito Abate R, Martini G, Santos C, Macarulla T, Argilés G, Capdevila J, Garcia A, Mulet N, Maiello E, Normanno N, Jones F, Tabernero J, Ciardello F, Salazar R, Vivancos A. Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer. Mol Oncol 2019;13:1827-35. [PMID: 31322322 DOI: 10.1002/1878-0261.12547] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
6 Morelli MP, Overman MJ, Dasari A, Kazmi SM, Mazard T, Vilar E, Morris VK, Lee MS, Herron D, Eng C, Morris J, Kee BK, Janku F, Deaton FL, Garrett C, Maru D, Diehl F, Angenendt P, Kopetz S. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol. 2015;26:731-736. [PMID: 25628445 DOI: 10.1093/annonc/mdv005] [Cited by in Crossref: 147] [Cited by in F6Publishing: 134] [Article Influence: 21.0] [Reference Citation Analysis]
7 Internò V, Tucci M, Pezzicoli G, Silvestris F, Porta C, Mannavola F. Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer. Front Oncol 2020;10:581130. [PMID: 33102237 DOI: 10.3389/fonc.2020.581130] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Jessup JM, Goldberg RM, Asare EA, Benson AB, Brierley JD, Chang GJ, Chen V, Compton CC, De Nardi P, Goodman KA, Gress D, Guinney J, Gunderson LL, Hamilton SR, Hanna NN, Kakar S, Kosinski LA, Negoita S, Ogino S, Overman MJ, Quirke P, Rohren E, Sargent DJ, Schumacher-penberthy LT, Shibata D, Sinicrope FA, Steele SR, Stojadinovic A, Tejpar S, Weiser MR, Welton ML, Washington MK. Colon and Rectum. In: Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR, editors. AJCC Cancer Staging Manual. Cham: Springer International Publishing; 2017. pp. 251-74. [DOI: 10.1007/978-3-319-40618-3_20] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
9 Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken J, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'hoore A, Diaz-rubio E, Douillard J, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne C, Labianca R, Laurent-puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen W, Papamichael D, Pentheroudakis G, Pfeiffer P, Price T, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll H, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology 2016;27:1386-422. [DOI: 10.1093/annonc/mdw235] [Cited by in Crossref: 1387] [Cited by in F6Publishing: 1250] [Article Influence: 231.2] [Reference Citation Analysis]
10 Sforza V, Martinelli E, Ciardiello F, Gambardella V, Napolitano S, Martini G, della Corte C, Cardone C, Ferrara ML, Reginelli A, Liguori G, Belli G, Troiani T. Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World J Gastroenterol 2016; 22(28): 6345-6361 [PMID: 27605871 DOI: 10.3748/wjg.v22.i28.6345] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 56] [Article Influence: 10.0] [Reference Citation Analysis]
11 Isnaldi E, Garuti A, Cirmena G, Scabini S, Rimini E, Ferrando L, Lia M, Murialdo R, Tixi L, Carminati E, Panaro A, Gallo M, Grillo F, Mastracci L, Repetto L, Fiocca R, Romairone E, Zoppoli G, Ballestrero A. Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer. J Transl Med 2019;17:137. [PMID: 31036005 DOI: 10.1186/s12967-019-1879-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
12 Lavitrano M, Ianzano L, Bonomo S, Cialdella A, Cerrito MG, Pisano F, Missaglia C, Giovannoni R, Romano G, McLean CM, Voest EE, D'Amato F, Noli B, Ferri GL, Agostini M, Pucciarelli S, Helin K, Leone BE, Canzonieri V, Grassilli E. BTK inhibitors synergise with 5-FU to treat drug-resistant TP53-null colon cancers. J Pathol 2020;250:134-47. [PMID: 31518438 DOI: 10.1002/path.5347] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
13 Simbolo M, Mafficini A, Agostini M, Pedrazzani C, Bedin C, Urso ED, Nitti D, Turri G, Scardoni M, Fassan M. Next-generation sequencing for genetic testing of familial colorectal cancer syndromes. Hered Cancer Clin Pract. 2015;13:18. [PMID: 26300997 DOI: 10.1186/s13053-015-0039-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
14 Ciombor KK, Haraldsdottir S, Goldberg RM. How Can Next-Generation Sequencing (Genomics) Help Us in Treating Colorectal Cancer? Curr Colorectal Cancer Rep 2014;10:372-9. [PMID: 25395895 DOI: 10.1007/s11888-014-0244-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
15 Cherri S, Libertini M, Zaniboni A. New drugs for the treatment of metastatic colorectal cancer. World J Gastrointest Oncol 2021; 13(11): 1551-1560 [PMID: 34853636 DOI: 10.4251/wjgo.v13.i11.1551] [Reference Citation Analysis]
16 Gonzalez RS, Washington K, Shi C. Current applications of molecular pathology in colorectal carcinoma. Appl Cancer Res 2017;37. [DOI: 10.1186/s41241-017-0020-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
17 Bruera G, Pepe F, Malapelle U, Pisapia P, Mas AD, Di Giacomo D, Calvisi G, Troncone G, Ricevuto E. KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy. Oncotarget 2018;9:26279-90. [PMID: 29899858 DOI: 10.18632/oncotarget.25180] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
18 Demkow U. Next Generation Sequencing in Pharmacogenomics. Clinical Applications for Next-Generation Sequencing. Elsevier; 2016. pp. 217-40. [DOI: 10.1016/b978-0-12-801739-5.00011-8] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
19 Van Krieken JH, Rouleau E, Ligtenberg MJ, Normanno N, Patterson SD, Jung A. RAS testing in metastatic colorectal cancer: advances in Europe. Virchows Arch 2016;468:383-96. [PMID: 26573425 DOI: 10.1007/s00428-015-1876-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
20 Løes IM, Immervoll H, Sorbye H, Angelsen JH, Horn A, Knappskog S, Lønning PE. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. Int J Cancer 2016;139:647-56. [PMID: 26991344 DOI: 10.1002/ijc.30089] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 8.0] [Reference Citation Analysis]
21 Ciardiello F, Normanno N, Martinelli E, Troiani T, Pisconti S, Cardone C, Nappi A, Bordonaro AR, Rachiglio M, Lambiase M. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. Ann Oncol. 2016;27:1055-1061. [PMID: 27002107 DOI: 10.1093/annonc/mdw136] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
22 Normanno N, Pinto C, Castiglione F, Fenizia F, Barberis M, Marchetti A, Fontanini G, De Rosa G, Taddei GL. The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences. J Transl Med 2015;13:287. [PMID: 26335936 DOI: 10.1186/s12967-015-0655-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
23 Mirone G, Shukla A, Marfe G. Signaling mechanisms of resistance to EGFR- and Anti-Angiogenic Inhibitors cancer. Crit Rev Oncol Hematol 2016;97:85-95. [PMID: 26364891 DOI: 10.1016/j.critrevonc.2015.08.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
24 Cardone C, Blauensteiner B, Moreno-Viedma V, Martini G, Simeon V, Vitiello PP, Ciardiello D, Belli V, Matrone N, Troiani T, Morgillo F, Zito Marino F, Dentice M, Nappi A, Boccaccino A, Antoniotti C, Cremolini C, Pietrantonio F, Prager GW, Normanno N, Maiello E, Argiles G, Elez E, Signoriello G, Franco R, Falcone A, Tabernero J, Sibilia M, Ciardiello F, Martinelli E. AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. Eur J Cancer 2020;138:1-10. [PMID: 32818762 DOI: 10.1016/j.ejca.2020.07.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
25 Fujiyoshi K, Yamaguchi T, Kakuta M, Takahashi A, Arai Y, Yamada M, Yamamoto G, Ohde S, Takao M, Horiguchi SI, Natsume S, Kazama S, Nishizawa Y, Nishimura Y, Akagi Y, Sakamoto H, Akagi K. Predictive model for high-frequency microsatellite instability in colorectal cancer patients over 50 years of age. Cancer Med 2017;6:1255-63. [PMID: 28544821 DOI: 10.1002/cam4.1088] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
26 Geredeli C, Yasar N. FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer. World J Surg Oncol 2018;16:67. [PMID: 29587749 DOI: 10.1186/s12957-018-1359-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Zhou J, Ji Q, Li Q. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. J Exp Clin Cancer Res 2021;40:328. [PMID: 34663410 DOI: 10.1186/s13046-021-02130-2] [Reference Citation Analysis]
28 Foster JM, Patel A, Zhang C, Shostrom V, Brown K, Cushman-Vokoun AM. Investigating the utility of extended mutation analysis in gastrointestinal peritoneal metastasis. J Surg Oncol 2020;122:1106-13. [PMID: 32662065 DOI: 10.1002/jso.26114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Tack V, Ligtenberg MJL, Siebers AG, Rombout PDM, Dabir PD, Weren RDA, van Krieken JHJM, Dequeker EMC. RAS testing for colorectal cancer patients is reliable in European laboratories that pass external quality assessment. Virchows Arch 2018;472:717-25. [DOI: 10.1007/s00428-017-2291-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
30 Mennini FS, Marcellusi A, Fabiano G, Rimassa L, Santoro A, Personeni N. Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer. Future Oncol 2019;15:2107-12. [PMID: 31161795 DOI: 10.2217/fon-2018-0904] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
31 Martinelli E, Ciardiello D, Martini G, Troiani T, Cardone C, Vitiello PP, Normanno N, Rachiglio AM, Maiello E, Latiano T, De Vita F, Ciardiello F. Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. Ann Oncol 2020;31:30-40. [PMID: 31912793 DOI: 10.1016/j.annonc.2019.10.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 29.0] [Reference Citation Analysis]
32 Dotolo S, Marabotti A, Rachiglio AM, Esposito Abate R, Benedetto M, Ciardiello F, De Luca A, Normanno N, Facchiano A, Tagliaferri R. A multiple network-based bioinformatics pipeline for the study of molecular mechanisms in oncological diseases for personalized medicine. Brief Bioinform 2021:bbab180. [PMID: 34050359 DOI: 10.1093/bib/bbab180] [Reference Citation Analysis]
33 Kotani D, Bando H, Taniguchi H, Masuishi T, Komatsu Y, Yamaguchi K, Nakajima T, Satoh T, Nishina T, Esaki T, Nomura S, Takahashi K, Iida S, Matsuda S, Motonaga S, Fuse N, Sato A, Fujii S, Ohtsu A, Ebi H, Yoshino T. BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer. ESMO Open 2020;5:e000624. [PMID: 33551068 DOI: 10.1136/esmoopen-2019-000624] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Di Paolo A, Polillo M, Lastella M, Bocci G, Del Re M, Danesi R. Methods: for studying pharmacogenetic profiles of combination chemotherapeutic drugs. Expert Opin Drug Metab Toxicol 2015;11:1253-67. [PMID: 26037261 DOI: 10.1517/17425255.2015.1053460] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Lupini L, Bassi C, Mlcochova J, Musa G, Russo M, Vychytilova-Faltejskova P, Svoboda M, Sabbioni S, Nemecek R, Slaby O, Negrini M. Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients. BMC Cancer 2015;15:808. [PMID: 26508446 DOI: 10.1186/s12885-015-1752-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 4.7] [Reference Citation Analysis]
36 Pinto C, Normanno N, Orlandi A, Fenizia F, Damato A, Maiello E, Tamburini E, Di Costanzo F, Tonini G, Bilancia D, Corsi D, Pisconti S, Ferrau F, Gori S, Daniele B, Zaniboni A, Soto Parra H, Frassinetti GL, Iaffaioli RV, Cassata A, Zampino MG, Repetto L, Calegari MA, Barone C; all the investigators of ERMES study group. Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC. Future Oncol 2018;14:1339-46. [PMID: 29846100 DOI: 10.2217/fon-2017-0592] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
37 Normanno N, Esposito Abate R, Lambiase M, Forgione L, Cardone C, Iannaccone A, Sacco A, Rachiglio AM, Martinelli E, Rizzi D, Pisconti S, Biglietto M, Bordonaro R, Troiani T, Latiano TP, Giuliani F, Leo S, Rinaldi A, Maiello E, Ciardiello F; CAPRI-GOIM Investigators. RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. Ann Oncol 2018;29:112-8. [PMID: 28950295 DOI: 10.1093/annonc/mdx417] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 16.7] [Reference Citation Analysis]
38 Chen B, Zheng D, Yu W, Huang C, Ye J, Han G, Zhuang J. Cetuximab versus bevacizumab maintenance following prior 8-cycle modified FOLFOXIRI plus cetuximab in Asian postmenopausal women with treatment-naive KRAS and BRAF wild-type metastatic colorectal cancer. J Int Med Res 2020;48:300060520930440. [PMID: 32993393 DOI: 10.1177/0300060520930440] [Reference Citation Analysis]
39 Boleij A, Tops BB, Rombout PD, Dequeker EM, Ligtenberg MJ, van Krieken JH; Dutch RAS EQA Initiative. RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers. Oncotarget 2015;6:15681-9. [PMID: 25944693 DOI: 10.18632/oncotarget.3804] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
40 Malapelle U, Vigliar E, Sgariglia R, Bellevicine C, Colarossi L, Vitale D, Pallante P, Troncone G. Ion Torrent next-generation sequencing for routine identification of clinically relevant mutations in colorectal cancer patients. J Clin Pathol 2015;68:64-8. [PMID: 25378536 DOI: 10.1136/jclinpath-2014-202691] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 7.6] [Reference Citation Analysis]
41 Lai E, Pretta A, Impera V, Mariani S, Giampieri R, Casula L, Pusceddu V, Coni P, Fanni D, Puzzoni M, Demurtas L, Ziranu P, Faa G, Scartozzi M. BRAF-mutant colorectal cancer, a different breed evolving. Expert Review of Molecular Diagnostics 2018;18:499-512. [DOI: 10.1080/14737159.2018.1470928] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
42 Mauri G, Gori V, Bonazzina E, Amatu A, Tosi F, Bencardino K, Ruggieri L, Patelli G, Arena S, Bardelli A, Siena S, Sartore-Bianchi A. Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities. Cancer Treat Rev 2020;91:102112. [PMID: 33091698 DOI: 10.1016/j.ctrv.2020.102112] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
43 Rachiglio AM, Lambiase M, Fenizia F, Roma C, Cardone C, Iannaccone A, De Luca A, Carotenuto M, Frezzetti D, Martinelli E, Maiello E, Ciardiello F, Normanno N. Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents. Cancers (Basel) 2019;11:E859. [PMID: 31226844 DOI: 10.3390/cancers11060859] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
44 Chan DLH, Segelov E, Wong RS, Smith A, Herbertson RA, Li BT, Tebbutt N, Price T, Pavlakis N. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. Cochrane Database Syst Rev. 2017;6:CD007047. [PMID: 28654140 DOI: 10.1002/14651858.cd007047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Del Carmen S, Sayagués JM, Bengoechea O, Anduaga MF, Alcazar JA, Gervas R, García J, Orfao A, Bellvis LM, Sarasquete ME, Del Mar Abad M. Spatio-temporal tumor heterogeneity in metastatic CRC tumors: a mutational-based approach. Oncotarget 2018;9:34279-88. [PMID: 30344942 DOI: 10.18632/oncotarget.26081] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
46 Ciardiello D, Martini G, Famiglietti V, Napolitano S, De Falco V, Troiani T, Latiano TP, Ros J, Elez Fernandez E, Vitiello PP, Maiello E, Ciardiello F, Martinelli E. Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers (Basel) 2021;13:1941. [PMID: 33920531 DOI: 10.3390/cancers13081941] [Reference Citation Analysis]
47 Roscilli G, De Vitis C, Ferrara FF, Noto A, Cherubini E, Ricci A, Mariotta S, Giarnieri E, Giovagnoli MR, Torrisi MR, Bergantino F, Costantini S, Fenizia F, Lambiase M, Aurisicchio L, Normanno N, Ciliberto G, Mancini R. Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity. J Transl Med 2016;14:61. [PMID: 26928703 DOI: 10.1186/s12967-016-0816-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
48 Feng Q, Wei Y, Ren L, Zheng P, Yu Y, Ye Q, Ding J, Chen J, Chang W, Zhong Y, Zhu D, Lin Q, Yang L, Qin X, Xu J. Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study. Oncotarget 2016;7:11380-96. [PMID: 26863631 DOI: 10.18632/oncotarget.7193] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
49 Mauri G, Pizzutilo EG, Amatu A, Bencardino K, Palmeri L, Bonazzina EF, Tosi F, Carlo Stella G, Burrafato G, Scaglione F, Marsoni S, Siravegna G, Bardelli A, Siena S, Sartore-Bianchi A. Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. Cancer Treat Rev 2019;73:41-53. [PMID: 30616224 DOI: 10.1016/j.ctrv.2018.12.006] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
50 Napolitano S, Martini G, Martinelli E, Della Corte CM, Morgillo F, Belli V, Cardone C, Matrone N, Ciardiello F, Troiani T. Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells. Oncotarget 2017;8:82773-83. [PMID: 29137301 DOI: 10.18632/oncotarget.19797] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
51 Martinelli E, Troiani T, Sforza V, Martini G, Cardone C, Vitiello PP, Ciardiello D, Rachiglio AM, Normanno N, Sartore-Bianchi A, Marsoni S, Bardelli A, Siena S, Ciardiello F. Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. ESMO Open. 2018;3:e000299. [PMID: 29387480 DOI: 10.1136/esmoopen-2017-000299] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
52 Kidess-Sigal E, Liu HE, Triboulet MM, Che J, Ramani VC, Visser BC, Poultsides GA, Longacre TA, Marziali A, Vysotskaia V, Wiggin M, Heirich K, Hanft V, Keilholz U, Tinhofer I, Norton JA, Lee M, Sollier-Christen E, Jeffrey SS. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer. Oncotarget 2016;7:85349-64. [PMID: 27863403 DOI: 10.18632/oncotarget.13350] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 13.5] [Reference Citation Analysis]
53 Pek M, Yatim SMJM, Chen Y, Li J, Gong M, Jiang X, Zhang F, Zheng J, Wu X, Yu Q. Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer. Oncogene 2017;36:4975-86. [DOI: 10.1038/onc.2017.120] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 6.4] [Reference Citation Analysis]
54 Del Vecchio F, Mastroiaco V, Di Marco A, Compagnoni C, Capece D, Zazzeroni F, Capalbo C, Alesse E, Tessitore A. Next-generation sequencing: recent applications to the analysis of colorectal cancer. J Transl Med. 2017;15:246. [PMID: 29221448 DOI: 10.1186/s12967-017-1353-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
55 Blank A, Roberts DE 2nd, Dawson H, Zlobec I, Lugli A. Tumor Heterogeneity in Primary Colorectal Cancer and Corresponding Metastases. Does the Apple Fall Far From the Tree? Front Med (Lausanne) 2018;5:234. [PMID: 30234115 DOI: 10.3389/fmed.2018.00234] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
56 Normanno N, Cree IA. Genomics driven-oncology: challenges and perspectives. BMC Cancer 2015;15:141. [PMID: 25884512 DOI: 10.1186/s12885-015-1147-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
57 Shinozaki E, Yoshino T, Yamazaki K, Muro K, Yamaguchi K, Nishina T, Yuki S, Shitara K, Bando H, Mimaki S, Nakai C, Matsushima K, Suzuki Y, Akagi K, Yamanaka T, Nomura S, Fujii S, Esumi H, Sugiyama M, Nishida N, Mizokami M, Koh Y, Abe Y, Ohtsu A, Tsuchihara K. Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study. Br J Cancer 2017;117:1450-8. [PMID: 28972961 DOI: 10.1038/bjc.2017.308] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
58 Lu HJ, Lin JK, Chen WS, Jiang JK, Yang SH, Lan YT, Lin CC, Chang SC, Teng HW. Primary tumor location is an important predictive factor for wild-type KRAS metastatic colon cancer treated with cetuximab as front-line bio-therapy. Asia Pac J Clin Oncol. 2016;12:207-215. [PMID: 26935130 DOI: 10.1111/ajco.12469] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
59 Haley L, Tseng LH, Zheng G, Dudley J, Anderson DA, Azad NS, Gocke CD, Eshleman JR, Lin MT. Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers. Mod Pathol 2015;28:1390-9. [PMID: 26226847 DOI: 10.1038/modpathol.2015.86] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 6.0] [Reference Citation Analysis]
60 Parseghian CM, Napolitano S, Loree JM, Kopetz S. Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies. Clin Cancer Res 2019;25:6899-908. [PMID: 31263029 DOI: 10.1158/1078-0432.CCR-19-0823] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 8.7] [Reference Citation Analysis]
61 Normanno N, Rachiglio AM, Lambiase M, Martinelli E, Fenizia F, Esposito C, Roma C, Troiani T, Rizzi D, Tatangelo F. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. Ann Oncol. 2015;26:1710-1714. [PMID: 25851630 DOI: 10.1093/annonc/mdv176] [Cited by in Crossref: 90] [Cited by in F6Publishing: 89] [Article Influence: 12.9] [Reference Citation Analysis]
62 Michel M, Kaps L, Maderer A, Galle PR, Moehler M. The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy. Cancers (Basel) 2021;13:2296. [PMID: 34064974 DOI: 10.3390/cancers13102296] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
63 Huemer F, Thaler J, Piringer G, Hackl H, Pleyer L, Hufnagl C, Weiss L, Greil R. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie). BMC Cancer 2018;18:11. [PMID: 29298682 DOI: 10.1186/s12885-017-3955-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
64 Mizukami T, Izawa N, Nakajima TE, Sunakawa Y. Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives. Drugs 2019;79:633-45. [PMID: 30968289 DOI: 10.1007/s40265-019-01113-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
65 Hu Y, Tao SY, Deng JM, Hou ZK, Liang JQ, Huang QG, Li LH, Li HB, Chen YM, Yi H, Chen XL, Liu H. Prognostic Value of NRAS Gene for Survival of Colorectal Cancer Patients: A Systematic Review and Meta-Analysis. Asian Pac J Cancer Prev. 2018;19:3001-3008. [PMID: 30484984 DOI: 10.31557/apjcp.2018.19.11.3001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
66 Martinelli E, Cardone C, Troiani T, Normanno N, Pisconti S, Sforza V, Bordonaro AR, Rachiglio AM, Lambiase M, Latiano TP, Modoni G, Cordio S, Giuliani F, Biglietto M, Montesarchio V, Barone C, Tonini G, Cinieri S, Febbraro A, Rizzi D, De Vita F, Orditura M, Colucci G, Maiello E, Ciardiello F, Iaffaioli V, Nasti G, Nappi A, Botti G, Tatangelo F, Chicchinelli N, Montrone M, Sebastio A, Guarino T, Simone G, Graziano P, Chiarazzo C, Maggio G, Longhitano L, Manusia M, Cartenì G, Nappi O, Micheli P, Leo L, Rossi S, Cassano A, Tommaselli E, Giordano G, Sponziello F, Marino A, Rinaldi A, Romito S, Muda AO, Lorusso V, Leo S, Barni S, Grimaldi G, Aieta M. Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial. ESMO Open 2016;1:e000086. [PMID: 28848656 DOI: 10.1136/esmoopen-2016-000086] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
67 Punt CJ, Koopman M, Vermeulen L. From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol. 2017;14:235-246. [PMID: 27922044 DOI: 10.1038/nrclinonc.2016.171] [Cited by in Crossref: 239] [Cited by in F6Publishing: 236] [Article Influence: 39.8] [Reference Citation Analysis]
68 Roda D, Castillo J, Telechea-Fernández M, Gil A, López-Rodas G, Franco L, González-Rodríguez P, Roselló S, Pérez-Fidalgo JA, García-Trevijano ER, Cervantes A, Zaragozá R. EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells. PLoS One 2015;10:e0130543. [PMID: 26110767 DOI: 10.1371/journal.pone.0130543] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
69 Osumi H, Vecchione L, Keilholz U, Vollbrecht C, Alig AHS, von Einem JC, Stahler A, Striefler JK, Kurreck A, Kind A, Modest DP, Stintzing S, Jelas I. NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?-Case series and review of the literature. Eur J Cancer 2021;153:86-95. [PMID: 34153718 DOI: 10.1016/j.ejca.2021.05.010] [Reference Citation Analysis]
70 Takeda H, Sunakawa Y. Management of BRAF Gene Alterations in Metastatic Colorectal Cancer: From Current Therapeutic Strategies to Future Perspectives. Front Oncol 2021;11:602194. [PMID: 33842313 DOI: 10.3389/fonc.2021.602194] [Reference Citation Analysis]
71 Thierry AR, Pastor B, Jiang ZQ, Katsiampoura AD, Parseghian C, Loree JM, Overman MJ, Sanchez C, Messaoudi SE, Ychou M, Kopetz S. Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer. Clin Cancer Res. 2017;23:4578-4591. [PMID: 28400427 DOI: 10.1158/1078-0432.ccr-17-0232] [Cited by in Crossref: 48] [Cited by in F6Publishing: 29] [Article Influence: 9.6] [Reference Citation Analysis]
72 Tan DS, Tan DS, Tan IBH, Yan B, Choo SP, Chng WJ, Hwang WYK. Recommendations to improve the clinical adoption of NGS-based cancer diagnostics in Singapore. Asia Pac J Clin Oncol 2020;16:222-31. [PMID: 32301274 DOI: 10.1111/ajco.13339] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
73 Troiani T, Napolitano S, Della Corte CM, Martini G, Martinelli E, Morgillo F, Ciardiello F. Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. ESMO Open 2016;1:e000088. [PMID: 27843640 DOI: 10.1136/esmoopen-2016-000088] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 9.3] [Reference Citation Analysis]
74 Martini G, Troiani T, Cardone C, Vitiello P, Sforza V, Ciardiello D, Napolitano S, Della Corte CM, Morgillo F, Raucci A, Cuomo A, Selvaggi F, Ciardiello F, Martinelli E. Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. World J Gastroenterol 2017; 23(26): 4675-4688 [PMID: 28765689 DOI: 10.3748/wjg.v23.i26.4675] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 59] [Article Influence: 11.4] [Reference Citation Analysis]
75 Loree JM, Kopetz S. Recent developments in the treatment of metastatic colorectal cancer. Ther Adv Med Oncol 2017;9:551-64. [PMID: 28794806 DOI: 10.1177/1758834017714997] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 10.8] [Reference Citation Analysis]
76 Adua D, Di Fabio F, Ercolani G, Fiorentino M, Gruppioni E, Altimari A, Rojas Limpe FL, Normanno N, Pinna AD, Pinto C. Heterogeneity in the colorectal primary tumor and the synchronous resected liver metastases prior to and after treatment with an anti-EGFR monoclonal antibody. Mol Clin Oncol 2017;7:113-20. [PMID: 28685087 DOI: 10.3892/mco.2017.1270] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
77 Blanco-Calvo M, Concha Á, Figueroa A, Garrido F, Valladares-Ayerbes M. Colorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology Approach. Int J Mol Sci 2015;16:13610-32. [PMID: 26084042 DOI: 10.3390/ijms160613610] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 5.4] [Reference Citation Analysis]